CoChat

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Open access

The DOI matches its Crossref record; 153 of the 155 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-019-0864-7

Cites

153 of 154 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Remnant lipoproteins accumulate in the arterial wall where they elicit inflammation. This provides a mechanistic basis for a causal role in atherosclerosis. Adapted from Nordestgaard and Varbo [56] with permission. FFA, free fatty acids; LDL, low-density lipoproteins; LPL, lipoprotein lipase
Fig. 1 Remnant lipoproteins accumulate in the arterial wall where they elicit inflammation. This provides a mechanistic basis for a causal role in atherosclerosis. Adapted from Nordestgaard and Varbo [56] with permission. FFA, free fatty acids; LDL, low-density lipoproteins; LPL, lipoprotein lipaseCC BY · PubMed Central
Fig. 2 Genetic studies suggest novel approaches for the management of hypertriglyceridemia focused on key targets involved in the regulation of triglyceride-rich lipoprotein metabolism: apolipoprotein C-III (encoded by APOC3), angiopoietin-like proteins (ANGPTL) 3 and 4, apolipoprotein A V (apo A V) and lipoprotein lipase (LPL)0 [75–83]. IDL, intermediate-density lipoproteins; TG, triglycerides; VLDL, very low-density lipoproteins
Fig. 2 Genetic studies suggest novel approaches for the management of hypertriglyceridemia focused on key targets involved in the regulation of triglyceride-rich lipoprotein metabolism: apolipoprotein C-III (encoded by APOC3), angiopoietin-like proteins (ANGPTL) 3 and 4, apolipoprotein A V (apo A V) and lipoprotein lipase (LPL)0 [75–83]. IDL, intermediate-density lipoproteins; TG, triglycerides; VLDL, very low-density lipoproteinsCC BY · PubMed Central
Fig. 3 Structural organization of nuclear receptors. The ligand binding domain of PPARα includes the ligand dependent activation function 2 interface. PPRE, peroxisome proliferator response element
Fig. 3 Structural organization of nuclear receptors. The ligand binding domain of PPARα includes the ligand dependent activation function 2 interface. PPRE, peroxisome proliferator response elementCC BY · PubMed Central
Fig. 4 Transcriptional activation of PPARα is a three-part process
Fig. 4 Transcriptional activation of PPARα is a three-part processCC BY · PubMed Central
Fig. 5 Structures of a SPPARMα (pemafibrate) and PPARα (fenofibrate) showing shared and unique regions. This Y-structure of pemafibrate results in improved fit with the PPARα ligand binding site compared with fenofibrate (see Additional files 1, 2)
Fig. 5 Structures of a SPPARMα (pemafibrate) and PPARα (fenofibrate) showing shared and unique regions. This Y-structure of pemafibrate results in improved fit with the PPARα ligand binding site compared with fenofibrate (see Additional files 1, 2)CC BY · PubMed Central
Fig. 6 Differentiation of the pharmacological profile of a SPPARMα (pemafibrate) based on available data. ALT, alanine aminotransferase; apo apolipoprotein; AST, aspartate aminotransferase; C, cholesterol; FGF21, fibroblast growth factor 21; HDL, high-density lipoprotein; TG, triglycerides
Fig. 6 Differentiation of the pharmacological profile of a SPPARMα (pemafibrate) based on available data. ALT, alanine aminotransferase; apo apolipoprotein; AST, aspartate aminotransferase; C, cholesterol; FGF21, fibroblast growth factor 21; HDL, high-density lipoprotein; TG, triglyceridesCC BY · PubMed Central
Fig. 7 Design of the PROMINENT study with pemafibrate. Adapted from Pradhan et al. [144] with permission. BID, twice daily; HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; TG, triglycerides
Fig. 7 Design of the PROMINENT study with pemafibrate. Adapted from Pradhan et al. [144] with permission. BID, twice daily; HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; TG, triglyceridesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 154 references

Research works printed but not linked: 3

  1. Iwata H, Murakami K, Ricchiuto P, Singh S, Libby P, Aikawa E. The novel PPARα selective agonist K-877 suppresses pro-inflammatory pathways and experimental arterial lesion formation. Circ Res. 2014;115:e86–93 (Abstract 24160).
  2. Kastelein JJP, Senko Y, Hounslow N. K-877, a selective PPAR alpha modulator (SPPARM alpha), improves dyslipidaemia in statin-treated patients with type 2 diabetes mellitus. Eur Heart J. 2015;36:1048.
  3. Kastelein JJP, Senko Y, Hounslow N, Hovingh GK, Ginsberg HN. K-877, a selective PPAR alpha modulator (SPPARM alpha), ameliorates dyslipidaemia in patients with well-controlled LDL Cholesterol levels on statin therapy, without increases in serum creatinine. Eur Heart J. 2015;36:1048.

Cited by

See all 152

Metadata

Authors
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., Duriez, P., Eckel, R. H., Ezhov, M. V., Farnier, M., Ginsberg, H. N., Hermans, M. P., Ishibashi, S., Karpe, F., Kodama, T., Koenig, W., Krempf, M., Lim, S., Lorenzatti, A. J., McPherson, R., Nuñez-Cortes, J. M., Nordestgaard, B. G., Ogawa, H., Packard, C. J., Plutzky, J., Ponte-Negretti, C. I., Pradhan, A., Ray, K. K., Reiner, Ž., Ridker, P. M., Ruscica, M., Sadikot, S., Shimano, H., Sritara, P., Stock, J. K., Su, T.-C., Susekov, A. V., Tartar, A., Taskinen, M.-R., Tenenbaum, A., Tokgözoğlu, L. S., Tomlinson, B., Tybjærg-Hansen, A., Valensi, P., Vrablík, M., Wahli, W., Watts, G. F., Yamashita, S., Yokote, K., Zambon, A., & Libby, P.
Affiliations
  • Universidade de São Paulo (BR)
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
  • Brigham and Women's Hospital (US)
  • Sorbonne Université (FR)
  • UNSW Sydney (AU)
  • University of Milan (IT)
  • Université Laval (CA)
  • Inserm (FR)
  • University of Colorado Cancer Center (US)
  • CHU Dijon Bourgogne (FR)
  • Columbia University (US)
  • Cliniques Universitaires Saint-Luc (BE)
  • Jichi Medical University (JP)
  • Churchill Hospital (GB)
  • Research Center for Advanced Science and Technology, The University of Tokyo (JP)
  • Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
  • Seoul National University (KR)
  • Instituto Médico DAMIC (AR)
  • University of Ottawa (CA)
  • University of Copenhagen (DK)
  • National Cerebral and Cardiovascular Center (JP)
  • University of Glasgow (GB)
  • Boston University (US)
  • Imperial College London (GB)
  • University Hospital Centre Zagreb (HR)
  • Jaslok Hospital (IN)
  • University of Tsukuba (JP)
  • Mahidol University (TH)
  • National Taiwan University (TW)
  • Russian Medical Academy of Continuous Professional Education (RU)
  • University of Helsinki (FI)
  • Tel Aviv University (IL)
  • Hacettepe University (TR)
  • Chinese University of Hong Kong (HK)
  • Université Sorbonne Paris Nord (FR)
  • SIB Swiss Institute of Bioinformatics (CH)
  • The University of Western Australia (AU)
  • Rinku General Medical Center (JP)
  • Chiba University (JP)
  • University of Padua (IT)
Corresponding author
Fruchart, Jean-Charles
Venue
Cardiovascular Diabetology
Published
2019-06-04
Volume
18
Issue
1
Pages
71-71
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2948216318
Cited by
140
References
155
Citations by year
2026: 5 · 2025: 11 · 2024: 16 · 2023: 19 · 2022: 17 · 2021: 21 · 2020: 41 · 2019: 10
FWCI
7.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • Dr Med - University of Zagreb School of Medicine Digital Repository (acceptedVersion)
  • HAL (submittedVersion, cc-by)
  • IRIS (submittedVersion, cc-by)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DR-NTU (Nanyang Technological University) (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • uO Research (University of Ottawa) (submittedVersion, public-domain)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
  • Terrestrial Environment Research Center (University of Tsukuba) (submittedVersion)
Funders
  • Amgen
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Teva Pharmaceutical Industries
  • Regeneron Pharmaceuticals
  • Ionis Pharmaceuticals
  • Amarin Corporation
  • Kowa Company
  • Mylan
  • Daiichi-Sankyo
  • Astellas Pharma
  • Shionogi
  • Otsuka Pharmaceutical
  • Servier
  • Japan Society for the Promotion of Science (17H01558, 17H06395)
  • Daiichi Sankyo Europe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
atherogenic dyslipidemia, hypertriglyceridemia, low HDL cholesterol, type 2 diabetes, insulin resistance, residual cardiovascular risk, hepatic safety, renal safety, fibrates, precision medicine
MeSH terms
Animals, Hypolipidemic Agents, Benzoxazoles, Butyrates, Cardiovascular Diseases, Humans, Lipids, Risk Factors, Signal Transduction, Biomarkers, Treatment Outcome, Risk Assessment, Consensus, PPAR alpha, Dyslipidemias, Molecular Targeted Therapy, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. https://app.cochat.ai/papers/10.1186/s12933-019-0864-7
The paper
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., Duriez, P., Eckel, R. H., Ezhov, M. V., Farnier, M., Ginsberg, H. N., Hermans, M. P., Ishibashi, S., Karpe, F., Kodama, T., . . . Libby, P. (2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-019-0864-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.